We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
+$28.4M
(+1.3%)
Cap. Flow
-$577M
Cap. Flow
% of AUM
-26.84%
Top 10 Holdings %
Top 10 Hldgs %
29.86%
Holding
143
New
30
Increased
17
Reduced
35
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
|
+$75.8M |
| 2 |
THOR
THORATEC CORPORATION
THOR
|
+$31.1M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$30.7M |
| 4 |
Viatris
VTRS
|
+$27.4M |
| 5 |
Traws Pharma
TRAW
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
|
+$43.8M |
| 2 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$42.7M |
| 3 |
Nektar Therapeutics
NKTR
|
+$34M |
| 4 |
STJ
St Jude Medical
STJ
|
+$24M |
| 5 |
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
|
+$23.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.2% |
| 2 | Technology | 1.35% |
| 3 | Financials | 1.05% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AngioDynamics
ANGO
$558M
| $26.6M | 1.24% |
2,013,104
-638,362
| -24% | -$7.53M |
|
|
XNPT
27
DELISTED
XENOPORT, INC.
XNPT
| $26.2M | 1.22% |
4,605,976
+535,886
| +13% | +$2.8M |
|
|
28
Traws Pharma
TRAW
$10.2M
| $25.6M | 1.19% |
+17
| New | +$24.3M |
|
|
SPPI
29
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $25.4M | 1.18% |
3,031,750
+3,000,000
| +9,449% | +$24.3M |
|
30
Alnylam Pharmaceuticals
ALNY
$35.7B
| $24.5M | 1.14% |
383,158
-310,842
| -45% | -$15.5M |
|
31
Merck
MRK
$315B
| $22.6M | 1.05% |
497,800
-104,800
| -17% | -$4.78M |
|
|
AET
32
DELISTED
Aetna Inc
AET
| $22.6M | 1.05% |
353,000
+3,000
| +0.9% | +$192K |
|
|
ARIA
33
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $22.6M | 1.05% |
1,227,204
-37,900
| -3% | -$736K |
|
|
UAM
34
DELISTED
Universal American Corp
UAM
| $22.3M | 1.04% |
2,926,100
-138,903
| -5% | -$1.22M |
|
35
Sonida Senior Living
SNDA
$1.93B
| $22.2M | 1.03% |
+70,043
| New | +$23.7M |
|
|
RNA
36
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
| $21.3M | 0.99% |
+3,224,524
| New | +$75.8M |
|
37
Globus Medical
GMED
$10.5B
| $20.9M | 0.97% |
+1,197,765
| New | +$20.7M |
|
|
SGNT
38
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $20.7M | 0.96% |
1,014,863
-1,067,304
| -51% | -$23.8M |
|
39
PTC Therapeutics
PTCT
$6.52B
| $18.1M | 0.84% |
+845,027
| New | +$14.7M |
|
|
PCYC
40
DELISTED
PHARMACYCLICS INC
PCYC
| $17.6M | 0.82% |
127,030
-100,000
| -44% | -$11.1M |
|
41
Cardinal Health
CAH
$53.5B
| $16.9M | 0.79% |
325,000
-375,000
| -54% | -$19.1M |
|
|
AGN
42
DELISTED
Allergan Inc
AGN
| $16.7M | 0.78% |
184,955
-190,345
| -51% | -$17.1M |
|
43
Molina Healthcare
MOH
$11.7B
| $16.3M | 0.76% |
459,000
-111,000
| -19% | -$4.1M |
|
44
Insmed
INSM
$23.5B
| $14.5M | 0.68% |
930,750
+376,957
| +68% | +$4.79M |
|
|
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $14.2M | 0.66% |
2,617,586
| – | – |
|
46
CALL
Edwards Lifesciences
EW
$49.4B
| $13.9M | 0.65% |
1,200,000
| – | – |
|
|
QCOR
47
DELISTED
QUESTCOR PHARMA INC
QCOR
| $13.6M | 0.63% |
233,767
+223,767
| +2,238% | +$13.3M |
|
48
CALL
Teva Pharmaceuticals
TEVA
$37.3B
| $13.2M | 0.62% |
+350,000
| New | +$13.7M |
|
49
BioCryst Pharmaceuticals
BCRX
$2.36B
| $11.9M | 0.55% |
+1,632,360
| New | +$8.28M |
|
|
BLUE
50
DELISTED
bluebird bio
BLUE
| $11.4M | 0.53% |
+32,673
| New | +$12.1M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2013 Portfolio in Review
As of Q3 2013, Deerfield Management held 143 positions worth $2.15B, up 1.3% from $2.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Deerfield Management withdrew a net $577M in Q3 2013, closing 30 positions and reducing 35 holdings. Its most notable exit was OPTIMER PHARMACEUTICALS, INC. COM STK, an estimated $43.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.
Against the trend, Deerfield Management opened a new position in PROSENSA HLDGS N V ORD SHS (NLD) worth $21.3M.
- Deerfield Management's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 3,224,524 shares worth $21.3M.
- Deerfield Management added most to Spectrum Pharmaceuticals Inc in Q3 2013, an estimated $24.3M increase.
- Deerfield Management's biggest Q3 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $42.7M.
- Deerfield Management fully exited OPTIMER PHARMACEUTICALS, INC. COM STK in Q3 2013, selling an estimated $43.8M.
- Deerfield Management's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2013.
- Deerfield Management opened 30 new positions and closed 30 in Q3 2013.
- Deerfield Management's portfolio value rose 1.3% quarter-over-quarter to $2.15B.
Based on Deerfield Management's 13F filing for Q3 2013, filed 14 Nov 2013.